The OncLive Colorectal Cancer condition center page is a comprehensive resource for clinical news and expert insights on colorectal cancer treatment and management, with a focus on novel therapeutic strategies including checkpoint inhibitors and TKIs across lines of therapy. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in colorectal cancer.
May 10th 2024
During an OncLive Peer Exchange, a panel of expert clinicians in CRC discussed studies seeking to further define the role of MRD testing in CRC.
Medical Crossfire®: Critical Questions on Diagnosis, Sequencing, and Selection of Systemic and Radioligand Therapy Options for Patients with GEP-NETs
View More
Patient, Provider, and Caregiver Connection: Addressing Pediatric and AYA Patient Concerns While Managing Hodgkin Lymphoma
View More
Live “Hot Seat”: Experts Face Your Hot-Button Questions on Maximizing PARP Inhibitors in Patients With CRPC
View More
Everything You Need to Know About PARP Inhibitor Combinations in Prostate Cancer Care: Why? For Whom? And When?
View More
Multidisciplinary Management of TNBC: Immunotherapy, PARP, TROP2, Oh My!
View More
Community Practice Connections™: The Advent of TROP2-Targeted Treatment Approaches in HR+/HER2- Breast Cancer
View More
B-Cell Tumor Board: Rendering Real World Personalized Treatment Plans in CLL/SLL and MCL Through the Lens of Emerging BTKi Evidence
View More
Community Practice Connections™: 8th Annual School of Gastrointestinal Oncology®
View More
Community Practice Connections™: Controversies and Conversations About HER2- Expressing Breast Cancer…Advances in Management of HER2-Low to -Positive Disease
View More
Show Me the Data™: Do We Have Sea Change for Novel Approaches in HR+/HER2- Breast Cancer? CDK, PI3K/AKT, ADC, and Next-Gen SERD Strategies Assessed
View More
Cancer Summaries and Commentaries™: Clinical Updates from Chicago in Breast Cancer
View More
8th Annual School of Nursing Oncology™
August 10, 2024
Register Now!
Cancer Summaries and Commentaries™: Clinical Updates in RCC from Chicago
View More
2024 International Symposium of Gastrointestinal Oncology (ISGIO)
October 11-12, 2024
Register Now!
Applying New Evidence in Multiple Myeloma Care from Frontline to R/R Disease
View More
Community Practice Connections™: 5th Annual Precision Medicine Symposium – An Illustrated Tumor Board
View More
Medical Crossfire®: How Does Recent Evidence on PARP Inhibitors and Combinations Inform Treatment Planning for Prostate Cancer Now and In the Future?
View More
Medical Crossfire®: How Do Clinicians Integrate the Latest Evidence in Treating Ovarian Cancer to Personalize Care?
View More
How CEACAM5 Expression Can Be Measured and Leveraged in NSCLC Care: Current Developments & Future Therapeutic Opportunities
View More
Medical Crossfire®: Where Are We in the World of ADCs? From HER2 to CEACAM5, TROP2, HER3, CDH6, B7H3, c-MET and Beyond!
View More
Community Oncology Connections™: Overcoming Barriers to Testing, Trial Access, and Equitable Care in Cancer
View More
Translating New Evidence into Treatment Algorithms from Frontline to R/R Multiple Myeloma: How the Experts Think & Treat
View More
Medical Crossfire: How Has Iron Supplementation Altered Treatment Planning for Patients with Cancer-Related Anemia?
View More
Dialogues With the Surgeon on Integration of Systemic Therapies in Perioperative Settings for NSCLC: Looking at EGFR, ALK, IO, and Beyond…
View More
The Next Wave in Biliary Tract Cancers: Leveraging Immunogenicity to Optimize Patient Outcomes in an Evolving Treatment Landscape
View More
The Evolving Tool Box in Advanced HR+/HER2– Breast Cancer: What You Need to Know About Next-Generation SERDs, PI3K/AKT, ADCs, CDK4/6 and Beyond…
View More
Tumor-Infiltrating Lymphocyte Therapy Advances Into Melanoma
View More
Coffee Talk™: Navigating the Impact of HER2/3, TROP2, and PARP from Early Stage to Advanced Breast Cancer Care
View More
Community Practice Connections™: 9th Annual School of Gastrointestinal Oncology®
View More
Dr. Ruff Analyzes Overall Survival in the VELOUR Trial
February 1st 2013Paul Ruff, MD, from the Witwatersrand, Johannesburg, South Africa, discusses a time-course analysis of overall survival following treatment with ziv-aflibercept in patients with metastatic colorectal cancer, as observed in the VELOUR trial.
Extended Survival Benefit With Zaltrap Seen in Metastatic Colorectal Cancer
Patients with metastatic colorectal cancer whose disease had progressed despite treatment with oxaliplatin experienced an improvement in survival by switching to a regimen of ziv-aflibercept plus FOLFIRI.
Dr. Grady Discusses Molecular Subtypes in Colorectal Cancer
January 25th 2013William M. Grady, MD, from the Fred Hutchinson Cancer Research Center, discusses results from a study that examined the association of intrinsic subtypes of colorectal cancer with prognosis, chemotherapy response, and other factors.
Colorectal Cancer Prognosis and Response to Chemotherapy Vary by Molecular Subtype
Using a new classification system that categorizes colorectal cancers by tumor gene expression patterns, researchers have determined that tumor prognosis and response to adjuvant chemotherapy in CRC vary according to molecular subtype.
Controlling Progression in Patients With Metastatic Colorectal Cancer
The prognosis for patients with colorectal cancer has benefited greatly from the advent of advances in chemotherapy and new agents, with nearly threefourths of stage I patients surviving for at least 5 years after diagnosis.
Biomarker May Predict Response to Bevacizumab in mCRC
Researchers have identified a potential predictive marker for survival in cases of metastatic colorectal cancer (mCRC) treated with bevacizumab (Avastin), suggesting that patients who have the appropriate biomarker could experience a greater benefit when given the drug, whereas others who do not express the biomarker could be spared from receiving unnecessary therapy.
Bevacizumab Plus Second-Line Chemotherapy Extends Survival in Advanced Colorectal Cancer Patients
Bevacizumab plus chemotherapy as a second-line treatment for metastatic colorectal cancer improved survival among patients whose disease had progressed after first-line combination therapy with bevacizumab.